And supports the strong association of promoter region polymorphism in apolipoprotein C3 (APOC3) (rs2854117 [− 482C>T] and rs2854116 [− 455T > C]) found to be strongly associated with NAFLD and its associated diseases, hypertriglyceridemia, metabolic syndrome, and coronary artery disease [45–48]. Here, APOC3 is linked to metabolic dysfunction-associated steatotic liver disease.